Compte rendu du 38e congrès de l'American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, 27–31 octobre 1996

Coquard, R.; Bachaud, JM

doi:10.1016/s1278-3218(97)84061-9

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] This definition replaced the previous ASTRO definition of a rising PSA over three measurements. [4] BCR rates of up to 63% have been reported following EBRT with mean time to recurrence of 34 months. [1] …”

Section: Biochemical Recurrencementioning

confidence: 99%

Emerging Treatments for Recurrent Prostate Cancer

Hanna

Jones

2015

Future Oncol.

View full text Add to dashboard Cite

Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease. We consider salvage treatments aimed at those with local recurrence confined to the prostate gland, therapies for those presenting with metastatic recurrence and the approach to men presenting with a rising prostate-specific antigen but no demonstrable disease (M0). In general, men with recurrent disease are often under-represented in randomized clinical trials. Consequently, evidence to guide treatment for these men is often lacking and this needs to be addressed in order to improve and better define our approach to this problem in the future.

show abstract

Section: Biochemical Recurrencementioning

confidence: 99%

Emerging Treatments for Recurrent Prostate Cancer

Hanna

Jones

2015

Future Oncol.

View full text Add to dashboard Cite

show abstract

Localized prostate cancer

Ohori

Scardino

2002

Current Problems in Surgery

View full text Add to dashboard Cite

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

show abstract

Compte rendu du 38e congrès de l'American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, 27–31 octobre 1996

Cited by 3 publications

References 0 publications

Emerging Treatments for Recurrent Prostate Cancer

Emerging Treatments for Recurrent Prostate Cancer

Localized prostate cancer

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Contact Info

Product

Resources

About